Display of peptides or proteins in an ordered, repetitive array, such as on the surface of a virus-like particle, is known to induce an enhanced immune response relative to vaccination with the "free" protein antigen. The coat protein of Tobacco mosaic virus (TMV) can accommodate short peptide insertions into the primary sequence, but the display of larger protein moieties as genetic fusions to the capsid protein has not been possible. We employed a randomized library approach to introduce a reactive lysine at the externally located amino terminus of the coat protein, which facilitated biotinylation of the capsid. To characterize display of heterologous proteins on the virion surface, we bound a model antigen (green fluorescent protein (GFP)-streptavidin (SA), expressed and purified from plants) to the biotinylated TMV particles, creating a GFP-SA decorated virus particle. A GFP-SA tetramer loading of 26% was obtained, corresponding to approximately 2200 GFP moieties displayed per intact virion. We evaluated the immunogenicity of GFP decorated virions in both mice and guinea pigs and found augmented humoral IgG titers in both species, relative to unbound GFP-SA tetramer. Next, we fused an N-terminal fragment of the Canine oral papillomavirus L2 protein to streptavidin. With TMV display, the L2 protein fragment was significantly more immunogenic than uncoupled antigen when tested in mice. By demonstrating the presentation of whole proteins, this study expands the utility of TMV as a vaccine scaffold beyond that which is possible by genetic manipulation.
Introduction
Virus-like particles (VLPs) represented the first example of a recombinantly expressed vaccine, with the licensure in the mid 1980s of two hepatitis B vaccines based on yeast-derived hepatitis B surface antigen particles (HBsAg) (Hilleman, 1992) . Presently, subunit vaccines based on VLPs derived from the L1 capsid proteins of human papillomavirus (HPV) are in latestage clinical trials and have demonstrated remarkable efficacy against their targeted HPV subtypes (Harper et al., 2004; Villa et al., 2005) . The success of these antigens in inducing protective immunity is due in large part to their highly ordered and repetitive structure. The quasicrystalline nature of VLPs facilitates pattern recognition by the specific and innate immune systems and sustained antibody production as a consequence of efficient activation of B cells through surface Ig cross-linking (Bachmann et al., 1993 (Bachmann et al., , 1998 . The immunostimulatory properties of VLPs prompted their application as a platform for the display of defined linear epitopes from diverse pathogens, as well as self-antigens. However, for the most part, published reports do not address the duration of the protective immunity induced by these chimeric VLPs against the target pathogen. A notable exception is a recombinant chimeric HBsAg VLP, which displays a large fragment of the circumsporozoite protein from the malaria parasite Plasmodium falciparum. Several trials in humans have demonstrated that this vaccine induced both strong antibody and T cell responses, with Virology 348 (2006) 475 -488 www.elsevier.com/locate/yviro protection against multiple parasite genotypes. In spite of this, the protective immunity was relatively short lived, indicating that further optimization in vaccine composition is required, to elicit sufficient memory T helper (Th) cells to ensure an anamnestic response (Bojang et al., 2001; Stoute et al., 1998) .
Vaccines based on the display of only one or a few HLArestricted T cell epitopes on VLPs will limit the vaccine applicability to only a subset of the patient population (Birkett et al., 2002; Nardin et al., 2000) . The field therefore needs new methods to increase the number of pathogen specific CD4 + -T cell epitopes that may be displayed on VLPs, in order to remove limitation to certain HLA genotypes and to bolster induction of specific memory T cells. Also, as most pathogen-neutralizing epitopes are conformational, restriction to the display of short, linear peptide epitopes is a significant drawback of most VLP epitope display platforms. Solution of these problems necessitates an increase in the size of the protein fragment that is to be displayed, which increases the potential for introducing protein conformations that disrupt the capsid protein's primary sequence, preventing particle formation (Karpenko et al., 2000) . Improved structural understanding of capsid formation (Kratz et al., 1999) and genetic engineering approaches (Santa Cruz et al., 1996) have permitted the display of GFP as a genetic fusion to core antigen particles of hepatitis B (HBcAg) and to potato virus X (PVX). A single chain functional antibody (scFv) has also been displayed in the case of PVX (Smolenska et al., 1998) . However, GFP and scFvs are structurally compact, and the ability to extend this approach to proteins with more extended tertiary structures is unclear. Recently, the ectodomain of the outer surface protein A from Borrelia burgdorferi was fused to the HBcAg capsid (Nassal et al., 2005) . This fusion was particularly difficult to generate, and the final VLP preparation was heterogeneous in nature, also containing incomplete particles and polymorphic multimeric structures. In addition, these approaches may compromise the ability to recover purified VLP, particularly in the case of filamentous capsids such as PVX.
An alternative approach is to uncouple expression and purification of the capsid scaffold and the heterologous protein to be displayed, with subsequent conjugation of the desired antigen to the VLP surface. Using this strategy, biotinylated papillomavirus L1 VLPs were decorated with a streptavidin fusion of the self-polypeptide TNF-α. This composition elicited high-titer protective autoantibodies in a mouse model for type II collagen-induced arthritis (Chackerian et al., 2001) . Strategies based on bifunctional cross-linkers with cowpea mosaic virus (CPMV) (Chatterji et al., 2004) and HBcAg (Jegerlehner et al., 2002) as scaffolds have also been described. Here, we report the implementation of a platform for the display of whole foreign proteins on the surface of TMV, in which the protein for conjugation was also transiently expressed in planta via recombinant TMV vectors, and subsequently purified. To obtain a soluble scaffold for biotinylation that accumulated to high levels required the evolution of a recombinant TMV with a surface-exposed lysine. Streptavidin fusions of either GFP or an N-terminal fragment (aa 61-171) of the Canine oral papillomavirus L2 protein (COPV L2 61-171 ) were conjugated to this biotinylated, lysine modified TMV capsid, and these complexes were characterized. The papillomavirus minor capsid protein (L2) is a promising vaccine candidate, as it induces antibodies that can cross-neutralize different papillomavirus species, unlike the major capsid protein (L1), which induces strictly typespecific immunity. However, L2 is a poor immunogen and requires potent adjuvants for induction of protective antibodies (Pastrana et al., 2005; Roden et al., 2000) . Since our primary application of the TMV scaffold was to improve vaccine immunogenicity, we compared the immune response obtained with these VLP complexes to those generated by the free streptavidin fusion proteins.
Results

Generation of a soluble and high yielding lysine modified coat protein
Initially, to obtain a surface-exposed lysine, we engineered a rTMV that expressed a coat protein (CP) with the amino acids GKGAG fused to the N-terminus (LSB 2800). However, this recombinant virus was suboptimal for our studies; the yield of purified virion (Fig. 1A) was low (0.1-0.2 mg/g infected tissue). This construct also aggregated upon storage at 4°C (Fig. 1B) . To circumvent these problems, we used a library-based passage and selection scheme to select for viruses displaying a surfaceexposed lysine that retained solubility at high protein concentrations. A lysine was introduced at the N-terminus of the type U1 strain of TMV, with three randomized codons placed immediately upstream. Transcripts from approximately 3600 clones were pooled and inoculated onto Nicotiana benthamiana plants to generate a library of TMV CP mutants (library LSB 1295). Isolation of virion from systemically infected tissue selected for functional library members that possessed the desired purification characteristics. The purified virus was stored for 2-5 days at 4°C, at a concentration of 10 mg/ml or greater, to permit virion with a propensity for aggregation to settle. We then used the supernatant in three subsequent virus passages. A total of 74 isolates from this selected library were sequenced, and 11 unique CP fusions were identified (Table 1 ). All isolates had at least one acidic residue (glutamic acid or aspartic acid) one or two residues N-terminal of the fixed lysine residue. Together, this small collection of selected viruses suggests that one or more surface-exposed acidic residues are needed to mitigate the presence of the surface-exposed lysine. Eight of these individual isolates were transcribed and inoculated onto plants to compare yields with those obtained from virus LSB 2800 (Table 1) . Selected members of the LSB 1295 library represented a 10-to 70-fold yield improvement over virus LSB 2800, with recoveries that exceeded 7 mg/g infected tissue noted for isolate LSB 1295.10. On the basis of expression level and isolate frequency, LSB 1295.4, with the amino acid sequence ADFK at the CP N-terminus, was carried forward. We observed no precipitation of this evolved and selected recombinant virus (Fig. 1A) , which represents a significant improvement in virus physical properties relative to the original lysine-displaying recombinant (LSB 2800) (Fig. 1B) .
GFP-streptavidin and COPV L2 61-171 -streptavidin expression in planta Expression of the GFP-SA fusion in N. benthamiana plants using a modified TMV expression vector (Shivprasad et al., 1999) did not affect plant growth or biomass accumulation, with the expected mosaic phenotype observed on systemically infected tissue approximately 6 days post-inoculation. Near confluent fluorescence of the systemically infected tissue occurred 8-9 days following inoculation. The GFP-SA fusion was detectable in crude plant extracts (Figs. 1C; GJ), migrating as a single band with an apparent molecular weight of 40 kDa and of comparable intensity to the TMV CP band, which migrated at 21 kDa. The yield of purified fusion ranged from 60 to 120 mg/kg plant tissue processed. By MALDI-TOF mass spectrometry, the observed mass of the purified species was within 0.05% of 39,717.1 Da, corresponding to full-length GFP-SA, with the methionine cleaved and the N-terminal amine acetylated (data not shown). The tetrameric form of core streptavidin is stable at 60°C and below (Bayer et al., 1990) . To confirm tetramerization of GFP-SA, samples incubated at 60°C or 95°C in SDS-PAGE loading buffer were analyzed by gel electrophoresis (Fig. 1D) . At 60°C, the prominent species migrated between 150 and 200 kDa, indicative of tetramer formation, while at 95°C, the 40-kDa fusion monomer predominated, with a minor ∼12 kDa species also present. Similarly, we expressed COPV L2 61-171 -SA in planta using a TMV vector and found the yield of purified fusion to be SDS-PAGE analysis of crude homogenates from systemically infected N. benthamiana plants (GJ) and the purified virions (F). GJ samples were diluted 5-fold prior to loading. (B) Visual comparison of the rTMV solubility following storage for 10 days at 4°C and subsequently mixed to resuspend precipitate (indicated by arrow). Protein concentrations were LSB 2800, 0.8 mg/ml; LSB 1295.4, 13 mg/ml. (C) Purification of GFP-SA by iminobiotin affinity chromatography. S1, initial supernatant; S1 S, 25% ammonium sulfate supernatant, S1 P, 25% ammonium sulfate pellet; L, affinity chromatography (Fig. 1D ). In addition, mass spectrometry confirmed N-terminal methionine cleavage, and the principal species mass was within 0.05% of the expected value (24,894.8 Da; data not shown).
TMV biotinylation and complex formation with streptavidin fusion proteins
In vitro biotinylation of the surface-exposed lysine of LSB 1295.4 was accomplished using the commercially available Nhydroxysuccinimide (NHS) PEO 4 -biotin. LSB 1295.4 was combined with the NHS-PEO 4 -biotin reagent at either a 24-or 240-fold molar excess relative to the viral CP and incubated for up to 48 h at either room temperature or 4°C. Although biotin linker attachment to the 18 kDa CP represents only a 473-Da increase in molecular weight, it resulted in a discernable shift by gel electrophoresis ( Fig. 2A) permitting the extent of CP conjugation to be assessed. With a 24-fold excess of biotin linker, approximately 20% of the virus surface was conjugated ( Fig. 2A) , and biotinylation was confirmed by mass spectrometry (Fig. 2B) . To obtain fully biotinylated TMV, it was necessary to incubate the LSB 1295.4 virus preparation at room temperature in the presence of a 240-fold molar excess of the linker (Figs. 2A and C) . Under these conditions, we detected two additional minor bands by gel electrophoresis. This indicates conjugation of two or three biotins to a subset of the TMV capsid proteins. We also observed these minor species when we incubated type U1 CP with the biotin linker ( Fig. 2A) . The identity of the minor conjugation species was confirmed by mass spectrometry (data not shown). The biotinylated U1 CP and the multiply conjugated LSB 1295.4 capsid protein were detected, with comparable efficiency, by either a streptavidin horseradish peroxidase conjugate or the TMV vector expressed GFP-SA in Western blots (Figs. 2D and E) .
To array the recombinant protein-SA tetramers on the surface of the TMV, we used fully biotinylated virion preparations. The GFP-SA was present at a 1.3-fold molar excess relative to biotinylated CP, corresponding to a theoretical maximum loading of 710 tetramers per virion rod. Following incubation, the complex was isolated from unbound tetramer by sequential precipitation using either ammonium sulfate or PEG. Control reactions, employing non-biotinylated LSB 1295.4, demonstrated the specificity of the tetramer association (Fig. 3A) . The complex recovered following PEG precipitation was examined by electron microscopy and compared to the starting virus scaffold, with and without biotinylation (Fig. 3B) . The majority of the rods observed in the LSB 1295.4 virus preparation were of the expected length (300 nm) with a diameter of 18 nm. Complete biotinylation of the capsid proteins did not alter the size distribution of the virus. However, in the case of biotinylated TMV loaded with GFP-SA, we observed a notable reduction in rod length: approximately 90% of rods were below 200 nm in length with 50-100 nm rods predominating. A second electron dense layer, corresponding to the associated GFP-SA, was clearly visible, increasing the diameter of the rods to 29 nm (Fig. 3C) . After extensive examination, we could detect no partially coated or uncoated rods, suggesting complete coverage of the TMV capsid surface. When COPV L2 61-171 -SA was used in place of GFP-SA, a polydispersity in rod length was also observed (data not shown), and all TMV capsids exhibited a similar, additional electron dense layer (Fig. 3C) .
The rTMV/GFP-SA complex was further characterized by gel electrophoresis and Western blots (Figs. 3D-F). Incubation at 60°C, in the presence of SDS-PAGE loading buffer, resulted in complete disassociation of the TMV virion; however, the biotin/streptavidin linkage remained intact. The CP/tetramer association resulted in a band shift relative to the GFP-SA alone. With incubation at 95°C, the streptavidin/biotin linkage was broken, and the GFP-SA and biotinylated CP migrated as monomers (Fig. 3D ). To confirm that the tetramer band shift observed at 60°C was the result of biotinylated CP association, a Western blot was performed, with an anti-TMV polyclonal antiserum used as the probe (Fig. 3E) . The bands at N220 kDa, which represent the complex (Bt GFP SA), were detected and were also reactive when an anti-GFP (Fig. 3F ) or antistreptavidin (data not shown) polyclonal antibody was used as the probe. The control loading reactions, in which GFP-SA was combined with non-biotinylated LSB 1295.4 virus (I GFP SA), were analyzed in parallel. These samples were also subjected to sequential PEG precipitations. By gel electrophoresis, no GFP-SA was detected in the PEG precipitated control samples (Fig.  3D ). This was confirmed by Western blot (Fig. 3F) , indicating that the isolation procedure we employed for the rTMV/GFP-SA complex effectively eliminated free SA fusion tetramers. The rTMV/COPV L2 L2 61-171 -SA complexes were analyzed in parallel with similar results (data not shown).
Quantitative characterization of the rTMV/streptavidin fusion complexes by amino acid analysis
The analysis described in Fig. 3 provides a qualitative characterization of the complex generated but no information on the level of virion decoration by the streptavidin fusion. Initially, we used gel electrophoresis together with densitometric analysis of the Coomassie blue-stained bands to assess the extent of TMV loading. However, the intensity of staining by Coomassie brilliant blue is protein composition dependent (Compton and Jones, 1985; de Moreno et al., 1986) , preventing quantitation of the CP and streptavidin fusion using a single standard. Amino acid analysis was therefore investigated as an alternative to quantitatively determine streptavidin fusion loading. Since the full-length protein was determined to be the predominant species for the LSB 1295.4 CP and both streptavidin fusions, the amino acid composition of the complex components can be related to the total picomoles of each residue detected, by a series of linear algebraic equations. Five of these equations are listed below (Eq. (1)) for the rTMV/GFP-SA complex.
In the present case, there are only two unknowns, the picomoles of LSB 1295.4 CP and the picomoles of GFP-SA, so at the minimum, two of the equations listed above are required to define the complex. To determine the appropriate equations to employ, three independent amino acid analyses were performed for both the LSB 1295.4 virus and the GFP-SA, to compare the experimental compositions obtained to the known composition of each protein. Representative chromatograms for the LSB 1295.4 CP and GFP-SA are shown in Fig. 4 . A subset of the amino acids for which the known and experimental compositions agreed within ±3% were then used; the picomoles of GFP-SA was estimated from the picomoles of histidine in the complex, since this amino acid was unique to the fusion (Fig.  4B ), and this value was then employed in the equations for arginine, leucine, and asparagine/aspartic acid, to obtain an average for the picomoles of LSB 1295.4 CP present. The composition of the complex used as immunogen in the animal studies was determined to be an essentially equimolar ratio of GFP-SA to LSB 1295.4 CP (1.05:1.0). This translated into 559 SA fusion tetramers, or 2200 GFP molecules, displayed per intact virion. If we assume a 1:1 ratio between tetramer fusion and biotinylated CP, a loading of 26% was achieved. When we used this procedure for the rTMV/COPV L2 61-171 -SA complex, we found the level of streptavidin fusion association to be comparable (data not shown). As an internal control, the total picomoles of protein estimated by this composition-dependent procedure was employed to back-calculate protein concentration and this value compared to the concentration obtained using the data for all amino acids in a composition-independent calculation, based solely on the molecular weight of the individual amino acids. The two concentration values were consistently within 10% of one another. . Following acid hydrolysis of the purified proteins, the amino acids were separated by ion exchange chromatography. Peaks corresponding to the individual amino acids are identified using the one letter code. Nor, norleucine internal standard; NH 3 , ammonia peak from amide deamination reactions which occur during acid hydrolysis. Differences in the buffer/column system employed for panels A and B resulted in the observed shift in the elution position for the NH 3 peak relative to the amino acid peaks. The TMV CP lacks histidine (H), and this peak is therefore unique to the GFP-SA.
Preliminary evaluation of the immunological response to antigen decorated virions
We compared the humoral immune response generated by GFP or COPV L2 61-171 decorated virions with that obtained by immunization with the respective streptavidin fusion alone, in both mice and guinea pigs. For the mouse studies, antigen dose was normalized to 1 μg and 10 μg of GFP or 2 μg and 20 μg COPV L2 , with the antigen administered in the absence of adjuvant. A guinea pig study was also performed with GFP, using a 10 μg dose, and for a subset of animals, the antigen was co-administered with the adjuvant RIBI (Corixa, Hamilton, MT). For the GFP-based studies, an additional control consisted of GFP-SA combined with non-biotinylated LSB 1295.4 virus, in proportions mirroring the complex composition (Table 2 ). This group was included to differentiate between the effect of physical association with the TMV capsid and the presence of the capsid alone on the immune response.
After a single immunization, we observed augmented GFP specific antibody titers in a subset of mice from the groups administered rTMV/GFP-SA, relative to GFP-SA alone or the streptavidin fusion mixed with the LSB 1295.4 virus. An augmented response was observed at both the 1 μg and 10 μg GFP doses (Fig. 5A ). Following the second 1 μg GFP immunization, the mice administered the rTMV/GFP-SA (Bt GFP SA) showed a robust immune response with endpoint titers that were significantly higher (P value = 0.0001) than those observed within the groups administered the free GFP-SA in the presence or absence of non-biotinylated virus (Fig. 5B) . At the 10 μg GFP dose, the differentiation between groups was not as marked (data not shown). Conjugation of GFP to the TMV capsid also elicited an improved immune response in guinea pigs. After the second immunization, GFP-specific antibodies were present in the sera of both animals administered the Table 2 Experimental set-up for the animal studies to evaluate the immunogenicity of the rTMV/streptavidin antigen fusion complexes complex, while none were detectable in animals administered the mixture of GFP-SA and non-biotinylated virus (Fig. 5C ). When the antigens were administered with RIBI adjuvant, the differentiation between the groups was maintained with the mean antibody titers elicited by the complex being 5-to 20-fold higher than those observed with the free GFP-SA. With COPV L2 61-171 as the target antigen, we observed a similar immune response profile to that obtained with GFP. A clear augmentation in antibody titer was evident following a single 20 μg administration of the L2 protein fragment when the antigen was biotin-TMV capsid-associated ( Fig. 6A ; Bt L2 SA). This initial response was boosted significantly with re-administration of the TMV complexed antigen (Fig. 6B) . In contrast, the 20 μg dose of the COPV L2 61-171 alone (L2 SA) produced only limited boosting, and endpoint titers were on average 6-fold lower than for the complex immunized animals (Bt L2 SA) (P value b 0.0001). For the 2 μg COPV L2 61-171 dose, no group differentiation was observed following one dose of antigen, however, with TMV conjugation significant boosting occurred with antigen re-administration.
Discussion
TMV has proven an effective carrier for the display of foreign peptides, successfully eliciting a neutralizing immune response against numerous target pathogens and in one reported case, breaking B cell tolerance and inducing auto-reactive antibodies (reviewed in Pogue et al. (2002) ). However, the display of peptide fragments exceeding 25-30 amino acids as genetic fusions to the CP has been problematic and the amino acid composition of the epitope, whatever its size, influences its compatibility. To expand the utility of TMV as an antigen carrier and overcome the antigen size limitations associated with genetic modification, we investigated the use of a biotindecorated capsid for the presentation of antigen-streptavidin fusions. Biotin was introduced by using NHS-PEO 4 -biotin, an amine reactive conjugate of the vitamin. Although the TMV CP contains two lysine residues (amino acids 54 and 69), predicted to delineate the surface-exposed 60s loop, their reactivity with the biotin conjugate was low (Figs. 2D and E) , suggesting limited solvent exposure. Since the terminal amino group was also unreactive, owing to its acetylation in planta (Filner and Marcus, 1974) , the introduction of a surface-exposed amine was required. Initially, a lysine flanked by two glycine residues was fused to the N-terminus of CP, yielding the recombinant virus LSB 2800. When purified, this fusion had a propensity to aggregate, even at low protein concentrations (Fig. 1B) . The mechanism by which the addition of a basic residue results in such poor solubility characteristics is not clear. We employed a library-based approach to obtain a soluble TMV capsid with a solvent-exposed lysine, by introducing three random amino acids upstream of an N-terminal lysine. From the small number of isolates sequenced (Table 1) , a clear bias was evident for the introduction of acidic residues, suggesting the need to mitigate the presence of the added positive charge. Charge separation was also preferred, with one or two predominantly aromatic or aliphatic residues separating the acidic residue and the lysine for the majority of the isolates, virus LSB 1295.6 being the exception. Purified virus was obtained for 8 of the 11 isolates, and no correlation was observed between the frequency of a particular mitigating sequence and the rTMV yield. Virus titers obtained in every case represented a notable improvement over LSB 2800. Furthermore, the majority of the LSB 1295 virus series remained soluble when stored at greater than 10 mg/ml, as illustrated for LSB 1295.4 (Fig. 1B) , the rTMV carried forward in this study. Recently, Demir and Stowell (2002) generated a lysine modified virion by introducing a single amino acid mutation at the C-terminus of the native CP (denoted T158K). To permit comparison with the mitigating sequence capsids of the LSB 1295 library, we cloned, expressed and purified the T158K recombinant (data not shown). Purification was performed as outlined by Demir and Stowell, as well as by the modified Gooding and Hebert (1967) procedure that we employed for both LSB 2800 and the LSB 1295 virion series (see Materials and Methods), and identity was confirmed by mass spectrometry. The T158K mutant accumulation was 25-to 30-fold higher than for LSB 2800, with levels in the infected tissue reaching 3 mg/g fresh weight and depending on the purification route, yields of purified virus ranged from 0.9 to 1.5 mg/g fresh weight. To assess lysine accessibility, the T158K and LSB 1295.4 virus preparations were combined with NHS-PEO 4 -biotin. By protein gel electrophoresis, we observed a similar level of biotin conjugation to both the T158K and LSB 1295.4 virions, suggesting the degree of solvent exposure for the lysines in the two CP contexts was comparable. However, in our hands, the T158K virus showed a marked propensity to aggregate. When the T158K virus was centrifuged briefly, less than 10% remained in the supernatant, irrespective of the purification route employed. In contrast, when LSB 1295.4 virus was centrifuged in parallel, N98% remained soluble, highlighting the benefits of the mitigating sequence library approach (data not shown). Excessive aggregation of the TMV scaffold will probably hinder processing of the assembled complexes whether they be employed in vaccinology, other medicinal applications or for the formation of nanomolecular wires for electronic devices, as was proposed by others (Demir and Stowell, 2002) .
There are conflicting reports regarding the tolerance of TMV for the addition of positively charged amino acids. The display of two peptides tested by Bendahmane et al. (1999) , containing one or four basic residues, elicited necrotic lesions on the inoculated leaves, a phenomenon that could be counteracted by the introduction of acidic residues. Similarly for CPMV (Porta et al., 2003) and zucchini yellow mosaic virus (Kimalov et al., 2004) , systemic infectivity was reduced with an increase in pI of the displayed peptide. However, positively charged peptides fused to TMV that show no deleterious host phenotypes and which were easily purified have also been documented (Wu et al., 2003) . Our experience with positively charged epitopes spans this spectrum, with the purified virus fusions also showing a range of solubilities that can, in addition, be influenced by whether the peptide is inserted at the N or C terminus (LSBC, unpublished results). In sum, the data led us to conclude that generalizations are of limited benefit and that library based selection strategies similar to those we describe in this paper may constitute a relatively rapid approach to overcome the negative effects of any given epitope fused to TMV CP or other viral capsid proteins. We have employed this library-based approach for either lysine or cysteine display at the C-terminus of the TMV U1 CP (inserted between amino acids 155 and 156), as well as for the introduction of a surfaceexposed cysteine residue at either CP terminus. In all cases, the solubility and accumulation of these evolved recombinant virions were superior to the addition of either GKG or GCG, and the virions were compatible with multiple homo-and heterodimer linker chemistries (LSBC, unpublished results).
Modification of the native TMV CP was necessary because the amino acid side chains commonly targeted for modification were not represented on the virion surface. Recently, new linker modalities have been designed, which permit chemical modification of the native U1 CP and offer an alternative strategy to the use of a recombinant TMV scaffold for antigen display (Schlick et al., 2005) . Biotin peptide mimics offer yet another means for antigen display. The C-terminus of TMV has been successfully modified to display the streptavidin-specific heptapeptide sequence TLIAHPQ and tetramer association with this recombinant virion was demonstrated (Negrouk et al., 2004) . However, similar to 2-iminobiotin (Hofmann et al., 1980) , streptavidin affinity for this peptide mimic is orders of magnitude lower than for biotin, with disassociation occurring under acidic conditions. These characteristics will likely alter the immunological characteristics of the complex and may be attractive in certain cases. For example, rapid antigen unloading following uptake into the acidic lysosomal compartment may facilitate antigen cross-presentation, which is crucial in antiviral immunity (Lizee et al., 2003) . The breadth of choices in the available capsid scaffolds introduces the possibility of tailoring the vaccines characteristics to the generation of the most appropriate immune response for the target disease.
Typically streptavidin fusions are expressed in bacterial systems, and functional protein is recovered from the isolated inclusion bodies following solubilization and refolding (Kipriyanov et al., 1995; Sano and Cantor, 1991) with typical yields of a few milligrams per 100 ml of culture (Sano and Cantor, 2000) . In the case of antigens whose neutralizing epitopes are conformational in nature, there is always the concern that the native tertiary structure may not be recovered. The successful production of soluble and functional recombinant streptavidin in Escherichia coli has been reported (Gallizia et al., 1998) ; however, this approach does not yet appear to have been extended to streptavidin fusions. For mammalian pathogen antigens and self-antigens, eukaryotic expression systems may offer improved epitope authenticity and circumvent the need for protein refolding. There have only been a limited number of reports describing the expression of streptavidin and avidin in plants, and the production of fusions thereof has not been described. By employing a transient TMV vector expression system, plant development and foreign protein expression are temporally segregated, facilitating the expression of streptavidin fusion proteins in the absence of toxic side effects which have been observed when streptavidin is expressed in transgenic plants (Murray et al., 2002) . For the two TMV vector produced streptavidin fusions described here (GFP-SA and COPV L2 61-171 -SA), this permitted the recovery of 60-120 mg of functional tetramer/kg tissue, which compares favorably with bacterial expression and obviates the need for a refolding step.
Rigorous qualification of recombinant vaccine composition is critical if the products are to be developed commercially. We showed that amino acid analysis of the two component complexes permitted the quantitative determination of their composition. This approach can be extended to any protein complex, provided the individual components to be combined are sufficiently characterized, for example by mass spectrometry. Up to 18 linear algebraic equations can be derived relating the picomoles of each protein to the picomoles of a given amino acid, as outlined in Eq. (1). When only two components are present, this introduces a high degree of redundancy, permitting the independent determination of the moles of each protein using pairs of equations and averaging of the results. This procedure could in theory be extended to complexes consisting of up to 18 unique components, although consideration of amino acids sensitive to the protein hydrolysis procedure will reduce the number of valid equations. For example, cysteine, methionine, and tryptophan are destroyed during the 6 N HCl hydrolysis. Also for the stable amino acids, caution must be exercised in the equations chosen. As indicated in the Results, we selected only amino acids that were accurately and reproducibly quantified. For example, with the chromatography and peak integration parameters employed, the isoleucine composition was consistently underestimated by 16-18%. The equation based on this amino acid was not employed as the error would be propagated, yielding incorrect and/or potentially meaningless solutions, e.g., negative picomoles of a given protein component. In certain cases, it may be helpful to tag the peptide or protein that is conjugated to TMV, to facilitate quantitation of the conjugation efficiency; the TMV CP lacks histidine (Fig. 4A) , therefore, for this capsid a polyhistidine tag would be appropriate, as this would provide a unique signature in the chromatogram trace.
The size distribution of the biotinylated TMV capsids was altered following decoration with the streptavidin fusions, with the predominant rod length decreasing from 300 nm to 50-100 nm (Fig. 3B) . The assembly of neutravidin onto the surface of biotinylated TMV, already coated onto copper grids, has previously been reported (Demir and Stowell, 2002) . Although these authors showed a similar level of decoration to that we reported here, they made no comment regarding alterations to the particle size distribution. In our case, we subjected the decorated virions to a series of PEG precipitations to eliminate unbound streptavidin fusion prior to analysis. It is possible that fragmentation of the TMV conjugate rods occurred during this additional processing, although no change in the particle size distribution was observed for control samples (non-biotinylated TMV mixed with streptavidin fusion) processed in parallel. An alternative explanation is that the packing of the streptavidin tetramers onto the capsid surface exceeded a critical limit, resulting in rupture of the TMV rod. The SDS detergent, added at 2% w/v with no heating, disrupts TMV virion yielding free CP (data not shown), whereas biotinylated CP-streptavidin association can occur in the presence of SDS and is stable up to 60°C (Fig. 3D ). This disparity in stability suggests that the affinity of streptavidin for the biotinylated CP may be sufficient for rod breakage when the streptavidin fusion is present in excess of the packing limit, as was the case here. Since the extent of capsid surface biotinylation can be easily controlled (Fig. 2) , this possibility can be addressed experimentally and if necessary a level of biotinylation chosen that will give complete surface coverage, while maintaining intact 300 nm rods. The influence of the complex dimensions on the immune response may also merit investigation. Early studies in rabbits administered either 14 C-labeled TMV virions or disassociated CP demonstrated that the particulate nature of TMV resulted in improved uptake by and activation of antigen presenting cells, as the intact capsids were more effectively and rapidly transported from the site of injection to proximal lymph nodes, and then to the spleen (Loor, 1967) . Further studies with streptavidin fusion loaded rods, of different size distributions, would permit the influence of rod length on the potency of the immune response to be evaluated.
In the current study, we used GFP as a model antigen. Clearly, physical association of the streptavidin fusion tetramers to TMV capsids augmented the immune response induced by the TMV complexes, relative to free tetramer alone or tetramer mixed with non-biotinylated rods (Fig. 5) . After the second immunization, total IgG titers were improved 4-to 20-fold in both mice and guinea pigs, and with mice antibodies were detectable after the first immunization for animals administered the rTMV/GPF-SA complex. The robust immune responses to relatively small amounts of antigen in the absence of adjuvant led us to investigate whether the TMV-antigen coupling approach could be used to improve the immune response to an antigen that is notoriously poorly immunogenic-the minor capsid protein of papillomaviruses. We found that the boosting response obtained with COPV L2 61-171 -SA was significantly improved by TMV conjugation, which confirms the data we obtained with GFP coupling to TMV, and reinforces our conclusion that whole protein display on the TMV capsid is a generally applicable approach for the augmentation of the humoral immune response. Furthermore, we have observed that complex formation with TMV is a requirement for the robust induction of activated antigen-specific CD8 + T cells, which is necessary for vaccines that require a cellular immune response for efficacy (manuscript in preparation). These encouraging results have provided a rationale for ongoing studies in our laboratory, focusing on a series of antigen targets from human immunodeficiency virus, human papillomavirus, and their respective preclinical models. Facile systems for the display of heterologous proteins on the surface of icosahedral capsids and their therapeutic potential have been reported (Chackerian et al., 2001; Jegerlehner et al., 2002) . The current work extends capsid display for therapeutic applications to another geometry, that of rod-shaped capsids, thereby increasing the density with which whole antigens may be displayed compared to competing VLP systems. On a T = 3 particle such as hepatitis B core antigen VLP, 180 tetramers can be theoretically accommodated, while the capacity of a T = 7 particle such as papillomavirus is 420. The 26% loading obtained in the present study corresponds to 550 tetramers per intact 300 nm long virion, and for cases where the antigen fusion partner to streptavidin is smaller, a further increase in the TMV packing density is theoretically possible, while for the icosahedral platforms, it will remain constant.
Materials and methods
Generation of soluble tobacco mosaic virus displaying a surface-exposed lysine
The amino terminus of the TMV CP resides on the exterior of TMV particles, allowing amino acids fused to the N-terminus of the TMV CP to be displayed on the virion surface. Using standard molecular techniques, codons for the amino acid sequence glycine-lysine-glycine-alanine-glycine (GKGAG), were fused to the 5′ end of the TMV CP ORF in a plasmid containing the full-length cDNA clone of TMV RNA, under the control of the T7 RNA polymerase promoter. The resulting plasmid was named pLSB 2800. T7 transcripts of pLSB 2800 were inoculated onto N. benthamiana plants to generate LSB 2800 virion. (Recombinant virus names are based on the names of the plasmid-based cDNA clones. This nomenclature is followed throughout this manuscript). LSB 2800 was purified from systemically infected N. benthamiana plants, by a modification of the procedure of Gooding and Hebert (1967) . Briefly, the tissue was homogenized in 0.86 M NaCl, 0.04% w/v sodium metabisulfite (0.5 g of tissue/ml of buffer), adjusted to pH 5.0, heated to 47°C for 5 min, chilled and centrifuged at 6000 × g for 5 min. The clarified supernatant was subjected to two sequential PEG precipitations to recover the virus. This concentrated virus was extracted with 25% chloroform v/v, to remove host protein impurities and pigments that remained associated with the virus.
Due to LSB 2800 aggregation with storage, a library-based strategy was undertaken, to construct a recombinant TMV CP having both a surface-exposed lysine residue and high solubility. Using a PCR-based approach, three randomized codons and a lysine codon were fused to the 5′ end of the U1 CP ORF. The TMV CP gene and 3′ UTR were amplified from a full-length cDNA clone of the U1 strain of TMV (p801) using oligonucleotides JAL 613 (CGAACCATGGNNNNKNNKAAATCTTA-CAGTATCACTACTCCATCTCA) as a forward primer and JAL 590 (GCCAACACATCCGGGTACCTGGGCCCCTA) as a reverse primer. The resulting PCR product of about 800 bp was digested with NcoI (underlined in JAL 613 sequence) and KpnI (underlined in JAL 590 sequence) and ligated into NcoI, KpnI digested pJL 150/254 to produce the CP library, pLSB 1295. The pLSB 1295 library was transformed into DH5α E. coli and plated. DNA was prepared from a pool of about 3600 colonies of this library, linearized with KpnI and transcribed with T7 RNA polymerase using the T7 mMessage mMachine kit (Ambion, Austin, TX), according to manufacturers' instructions. Transcript was inoculated onto 12 N. benthamiana plants at a concentration of approximately 100 infectious units per plant.
Approximately 8-10 days post-inoculation, one systemically infected leaf from each N. benthamiana plant was harvested and pooled. TMV particles were purified from the pooled infected leaves as described above, by extracting in a buffer lacking NaCl and omitting the final chloroform treatment. The purified virus was passaged for three additional cycles, with the virus purified between each cycle. After the final virus purification, RNA was isolated using the Qiagen RNAeasy kit (Valencia, CA), according to the manufacturers' instructions. The CP gene was amplified from the purified viral RNA using the Promega ImPromII RT-PCR kit (Madison, WI) and the oligonucleotide JAL 619 (GCCTTGGTACCTGGGCCCCTACCGGGGG-TAACGG). The CP gene region and 3′ UTR were subsequently amplified from the RT reaction product using oligonucleotides JAL 618 (CGATGATGATTCGGAGGCTACTG) and JAL 619 as forward and reverse primers, respectively. The resulting PCR product was digested with NcoI and KpnI and ligated into NcoIKpnI digested pJL 150/254. This ligation reaction was transformed into DH5α E. coli, and DNA samples from individual colonies were sequenced to determine the coding sequence at the 5′ end of the CP gene for isolates from the selected library.
To obtain virus samples of recombinant clones from the selected library, transcript was generated, inoculated onto N. benthamiana plants and TMV particles purified from systemically infected tissue as described earlier. Individual virus samples were analyzed by protein gel electrophoresis, and mass spectrometry was performed to confirm the identity of the additional amino acids on the CP N-terminus.
Cloning, expression, and purification of the streptavidin fusions Purified Streptomyces avidinii genomic DNA was obtained from ATCC (Manassas, VA), and the streptavidin core (SA) coding sequence (372 bp covering amino acids 40-163 of the Swissprot accession number P22629) was amplified by PCR. The SA coding sequence was ligated to the SacI site in the GFP insert in the TMV expression vector, p30B GFPc3 (Shivprasad et al., 1999) , using standard cloning techniques, resulting in a fusion of GFP to the N-terminus of the streptavidin core. This plasmid, pLSB 1290, was modified further to remove the GFP and to introduce the NgoMIV and AvrII restriction sites at the Nterminus of the SA core to facilitate additional cloning (plasmid pLSB1821). A DNA fragment, corresponding to amino acids 61-171 of the L2 protein of COPV (Genbank accession number NP056818), COPV L2 61-171 , was synthesized by Geneart (Regensburg, Germany) using the preferred codon usage of tobacco. Following NgoMIV and AvrII digestion, the fragment was cloned into pLSB1821 to generate plasmid pLSB1825. Infectious transcripts, prepared from pLSB1290 or pLSB1825, were inoculated onto N. benthamiana plants.
To isolate the GFP-SA fusion, infected plant tissue was homogenized in three volumes of extraction buffer (100 mM phosphate pH 7.2, 0.01% Na-metabisulfite, 1 μl BME per ml) and filtered through cheesecloth. Following heat treatment at 52-55°C for 7 min, the homogenate was centrifuged at 12,000 × g for 10 min and an initial 25% ammonium sulfate cut performed on the clarified supernatant. The GFP-SA containing protein fraction was precipitated with 50% ammonium sulfate, resuspended to 1/5th the original volume, and dialyzed against 1× phosphate-buffered saline (PBS), adjusted to pH 9.3. For COPV L2 61-171 -SA, 25 mM Tris-maleic acid, pH 7.5, 2 mM EDTA was employed as the extraction buffer, the heat treatment omitted and 0.4% w/v polyethyleneimine added to facilitate clarification. A single 30% ammonium sulfate cut was performed to concentrate COPV L2 61-171 -SA.
Affinity chromatography was performed using an AKTA purifier 10 system (Amersham Biosciences, Piscataway, NJ). The clarified plant extract was adjusted to pH 11 and loaded onto an immobilized iminobiotin resin (Pierce, Rockford, IL) using 1 ml resin per 20 g tissue extracted. The captured streptavidin fusion was eluted using 0.1 M acetic acid, pH 4.0 and the peak fractions dialyzed against phosphate buffer prior to storage.
Biotinylation of the LSB 1295.4 rTMV surface-exposed lysine
From the library passage experiment, multiple unique recombinant viruses were obtained (Table 1) which remained soluble post-purification at concentrations of 10 mg/ml or higher. TMV recombinant LSB 1295.4 containing the Nterminal amino acids ADFK was selected for in vitro biotinylation reactions. Biotin was covalently conjugated to the surface-exposed lysine using EZ-Link NHS-PEO 4 -biotin (Pierce, Rockford, IL). Lyophilized NHS-PEO 4 -biotin was dissolved in phosphate buffer containing the rTMV at a concentration of 0.8 mg/ml, with the biotin analog typically present at a 24-fold or 240-fold molar excess. The conjugation reactions were incubated with mixing at either 4°C or room temperature, for up to 60 h, as described in the Results. Unreacted NHS-PEO 4 -biotin was removed by PEG precipitation of the biotinylated rTMV (4% w/v PEG, 4% w/v NaCl), and the biotinylated virus was resuspended in 1× PBS.
Analytical procedures, immunoassays, and electron microscopy
Polyacrylamide gel electrophoresis (PAGE) of proteins in the presence of sodium dodecyl sulfate (SDS) (Laemmli, 1970) was performed on 10-20% Tris glycine gels (BioRad, Hercules CA, or Invitrogen, Carlsbad, CA), following the manufacturers' instructions. The Mark 12 or Magic Mark XP proteins standards (both Invitrogen) were employed as molecular weight references. Western blots (Towbin et al., 1979) , employing 0.2 μm polyvinylidene fluoride membrane (BioRad) were probed with either rabbit anti-TMV polyclonal, PVAS-135D (ATCC) or a rabbit anti-GFP polyclonal (Polysciences, Warrington, PA). In both cases, the secondary antibody was a goat anti-rabbit horseradish peroxidase (HRP) conjugate (BioRad). To evaluate rTMV biotinylation, blots were probed with either streptavidin HRP (Pharmingen, San Diego, CA) or the GFP-SA fusion. HRP detection was with the ECL+ chemiluminescent kit (Amersham) with Hyperfilm ECL (Amersham) employed for image capture, as per the manufacturers' instructions.
Amino acid analysis (AAA) was performed by the Molecular Structure Facility at the University of California, Davis. Protein quantitation was also performed using the bicinchoninic acid (BCA) assay (Pierce) in a microtiter plate format following the manufacturers' instructions. Wild-type TMV, type U1, quantified by AAA was employed as a standard. Protein mass determination was performed by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) using a Voyager-DE STR Biospectrometry Workstation (Applied Biosystems, Foster City, CA). The mass spectrometer was operated in linear and positive mode using delayed extraction at an accelerating voltage of 25 kV and 128 laser shots per spectrum. A single point mass calibration was performed using horse heart apomyoglobin (Sigma, St. Louis, MO). All MALDI-TOF sample spotting in sinipinic acid was performed using a dried-droplet method (Karas and Hillenkamp, 1988) . All raw spectral data were processed using Applied Biosystems Data Explorer 4.0.0.0. Protein identification was determined using General Protein/Mass Analysis for Windows (GPMAW), version 5.0 (Lighthouse Data, Denmark) software.
For electron microscopy, grids (400 Mesh copper, carbon coated; Ted Pella, Redding, CA) were floated on drops of 1× PBS, containing rTMV or the rTMV/streptavidin fusion complex, diluted to a concentration of 100-200 μg/ml (relative to the rTMV alone). Following a 15-min contact time, excess liquid was removed, the grids negatively stained with 1% phosphotungstic acid (PTA) and permitted to air dry. Bacitracin at 25 μg/ml was employed during both the sample coating of the grid and negative staining (Gregory and Pirie, 1973) . All samples were examined on a Philips CM120 microscope, coupled to a Gatan MegaScan 795 digital camera.
Manufacture of the rTMV/streptavidin fusion complexes
Affinity purified GFP-SA was combined with biotinylated rTMV, to obtain a final GFP-SA to rTMV CP mass ratio of 3:1. For COPV L2 61-171 -SA, the mass ratio of streptavidin fusion to rTMV CP was 1.4:1. The mixture was incubated for 4 h or overnight at room temperature, with gentle agitation, to allow the streptavidin fusion to bind to the biotinylated virion. For the rTMV/GFP-SA mixtures, unbound GFP-SA was removed by precipitation of TMV particles with 4% PEG (MW 6000), 4% NaCl and centrifugation for 15 min at 10,000×g. The PEG precipitation steps were repeated twice, and a control incubation employing non-biotinylated rTMV was processed in parallel. Siliconized centrifuge tubes and pipettes were employed during the manufacturing.
Immunogenicity testing in mice and guinea pigs and serological analysis
The immunogenicity of the rTMV/GFP-SA complexes was evaluated in both mice and guinea pigs. The murine studies were performed using 6-to 8-week-old female BALB/c mice (Harlan Sprague-Dawley, Indianapolis, IN). Mice received two immunizations, administered subcutaneously at 2-week intervals in the absence of adjuvant. Tail bleeds were taken 9 days after each injection. All dosing was normalized to the mass of GFP administered, with animals receiving either 1 μg or 10 μg GFP. Groups of five mice were employed, and the high and low responders from each group were omitted in the analysis. For the guinea pig study, 20-week-old animals (Harlan SpragueDawley) (2 per group) received a total of two 10 μg GFP immunizations delivered at four sites along the back. For half the groups, the antigens were combined with the adjuvant RIBI (Corixa, Hamilton, MT), as per the manufacturers' instructions. Antigen was administered at 4-week intervals, with bleeds taken 2 weeks after each injection by intravenous puncture of the cranial vena cava. The murine study to test the COPV L2 61-171 -SA was similar in design to that described above, except that groups consisted of six animals, and the normalized COPV L2 61-171 doses were 2 μg or 20 μg. Table 2 summarizes the antigen groups evaluated for both the murine (M) and guinea pig (GP) studies.
Antibody response to antigen was determined by enzymelinked immunosorbent assay (ELISA). 96-well microtiter plates (MaxiSorp; Nalge Nunc, Rochester, NY) were coated with either GFP (TMV vector expressed and purified to N90%) or a bacterially expressed COPV L2 fragment (amino acids 38-160) in carbonate/bicarbonate buffer (pH 9.6). After blocking with bovine serum albumin, serial dilutions of the sera were added. Following a 1-h incubation, the plates were washed and incubated for an additional hour with the appropriate HRPconjugated secondary antibodies; goat anti-mouse IgG (Southern Biotechnology Associates, Birmingham, AL) or goat antiguinea pig IgG (Bethyl Laboratories, Montgomery, Texas). Plates were developed using a tetramethyl benzidine substrate solution (Turbo TMB ELISA; Pierce), and the reactions stopped by the addition of 1 N sulfuric acid. Plate absorbance was read at 450 nm in a 96-well plate spectrophotometer (Molecular Devices, Sunnyvale, CA). The serum endpoint dilution corresponded to an absorbance reading of twice background. Data and statistical analysis (unpaired t tests) was performed using GraphPad (version 4.0) (San Diego, CA).
